Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

NCT02238834 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: FP-025
DRUG: Placebo
DRUG: FP-025
DRUG: Placebo

Sponsor

Foresee Pharmaceuticals Co., Ltd.

Collaborators

[object Object]